Altimmune, Inc. — Director's Dealing 2023

Feb 2, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2023-01-31

Reporting Person: Garg Vipin K (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-31	Common Stock, par value $0.0001	A	1938	$10.2085	Acquired	229713	Direct
2023-02-01	Common Stock, par value $0.0001	M	16546	—	Acquired	246259	Direct
2023-02-01	Common Stock, par value $0.0001	F	7658	$13.78	Disposed	238601	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-01	Restricted Stock Units	$	M	16546	Disposed		Common Stock, par value $0.0001 (16546)	Direct

Footnotes

F1: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2022 through January 31, 2023.

F2: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2022.

F3: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.

F4: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.

F5: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.